Keyword Analysis & Research: cybord hemonc

hemonc.org

https://hemonc.org/wiki/Multiple_myeloma,_induction

WEBNote: In ECOG E4A03 this is the low-dose dexamethasone arm, and was intended for patients with previously untreated symptomatic multiple myeloma, bone marrow …

DA: 98 PA: 42 MOZ Rank: 66

hemonc.org

https://hemonc.org/wiki/Multiple_myeloma

IMWG international uniform response criteria for multiple myeloma. (Durie et al. Leukemia 2006) PubMed European Blood and Marrow Transplant (EBMT) criteria. (Bladé et al. Br J Hematol 1998) PubMed

IMWG international uniform response criteria for multiple myeloma. (Durie et al. Leukemia 2006) PubMed

European Blood and Marrow Transplant (EBMT) criteria. (Bladé et al. Br J Hematol 1998) PubMed

DA: 32 PA: 95 MOZ Rank: 64

nature.com

https://www.nature.com/articles/bmt2014288

DA: 46 PA: 84 MOZ Rank: 19

ashpublications.org

https://ashpublications.org/blood/article/119/19/4391/29983/Cyclophosphamide-bortezomib-dexamethasone-CyBorD

WEBMay 10, 2012 · CyBorD produces rapid and complete hematologic responses in the majority of patients with AL regardless of previous treatment or ASCT candidacy. It is … Author: Joseph R. Mikhael, Steven R. Schuster, Victor H. Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. R... Publish Year: 2012

Author: Joseph R. Mikhael, Steven R. Schuster, Victor H. Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. R...

Publish Year: 2012

DA: 15 PA: 70 MOZ Rank: 10

chemoexperts.com

https://www.chemoexperts.com/cybord.html

WEBCyBorD or VCd or cybord is given to alleviate symptoms and slow the progression of multiple myeloma, not for disease cure. After treatment, patients who respond to …

DA: 42 PA: 13 MOZ Rank: 20

ashpublications.org

https://ashpublications.org/blood/article/122/21/5396/13708/Cybord-Is-An-Active-Well-Tolerated-Cost-Effective

WEBNov 15, 2013 · Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience | Blood | American …

DA: 89 PA: 69 MOZ Rank: 69

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/

WEBIn summary, CyBorD with treatment given on a 28 day cycle is a highly active regimen in newly diagnosed MM and produces rapid and profound responses. The regimen is …

DA: 7 PA: 27 MOZ Rank: 75

ascopubs.org

https://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.8586

WEBMay 20, 2014 · Conclusions: CYBORD is an effective treatment regimen without significant increase in side effect profile for pts with relapsed/refractory MM, achieving better …

DA: 92 PA: 99 MOZ Rank: 24

ashpublications.org

https://ashpublications.org/blood/article/115/16/3416/27043/Once-versus-twice-weekly-bortezomib-induction

WEBApr 22, 2010 · After observing high response rates in relapsed multiple myeloma (MM) patients, 1 we examined a 3-drug combination of bortezomib, cyclophosphamide, and …

DA: 77 PA: 81 MOZ Rank: 36

nature.com

https://www.nature.com/articles/bmt2014288

WEBJan 19, 2015 · Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma …

DA: 44 PA: 34 MOZ Rank: 22